Publication

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Related publications (31)

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

Dendritic cells (DCs) are specialized myeloid cells with the ability to uptake, process, and present antigens to T lymphocytes. They also generate cytokine and chemokine gradients that regulate immune cell trafficking, activation, and function. Monocyte-de ...

EPFL2024

Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth

Freddy Radtke, Nadine Fournier, Amber Dawn Bowler, Etienne Meylan, Anita Bodac, Justine Pascual, Vincent Roh

Elevated peripheral blood and tumor-infiltrating neutrophils are often associated with a poor patient prognosis. However, therapeutic strategies to target these cells are difficult to implement due to the life-threatening risk of neutropenia. In a genetica ...

Springernature2024

Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

Aaron Simone Petruzzella

Cysteine cathepsins proteases are enzymes that play essential physiological roles, but their activity is also associated to different aspects of cancer progression and to the development of other diseases. Therefore, cysteine cathepsins are relevant and pr ...

EPFL2024

Exploration and modulation of mechanical cues for enhanced cancer immunotherapy

Armand Kurum

The advent of immunotherapy, such as immune checkpoint blockade (ICB) and adoptive transfer of cytotoxic lymphocytes, has transformed the clinical care of cancer. However, a significant proportion of patients are resistant to immunotherapy or experience re ...

EPFL2024

6-diazo-5-oxo-l-norleucine prodrugs

Xile Hu, Li Tang, Céline Jasmin Prange

The present invention relates to 6-diazo-5-oxo-L-norleucine prodrugs having reduced toxicity and increased tumor specificity and to their therapeutic use for treating cancer. ...

2024

Deconvolution of ex-vivo drug screening data and bulk tissue expression predicts the abundance and viability of cancer cell subpopulations

Alexandre Coudray

Ex-vivo drug sensitivity screening (DSS) allows the prediction of cancer treatment effectiveness in a personalized fashion. However, it only provides a readout on mixtures of cells, potentially occulting important information on clinically relevant cell su ...

EPFL2023

The role of LRRK2 in lung adenocarcinoma

Aspasia Gkasti

Lung cancer is the leading cause of cancer-related deaths worldwide and the most common lung cancer subtype is lung adenocarcinoma (LUAD). Frequently mutated genes involve activating mutations in KRAS and loss of function mutations in TP53. LUADs primarily ...

EPFL2024

Il-10 expressing cells for enhanced cancer immunotherapies

Li Tang, Yugang Guo, Yang Zhao

The present invention relates generally to the field of anti-cancer therapy, in particular to the use of adoptive T cell transfer therapy for treating cancer, in particular sold tumors. More specifically, the present invention relates to immune cells compr ...

2023

Unlocking Hidden Potential: Exploring the Complexities of Signaling in Immune Cell Activation to Optimize CAR Therapy

Mathieu Girardin

Chimeric antigen receptors (CARs) are synthetic, transmembrane proteins that trigger immune cell signaling following their engagement. They have been first utilized in T cells and later in natural killer (NK) cells to redirect their cytotoxicity toward a s ...

EPFL2023

Nanotechnology enabled modulation of T cell immunity for cancer treatment

Xiaomeng Hu

Recent breakthroughs in cancer immunotherapy, exemplified by immune checkpoint blockade and CAR T cell therapy, have achieved remarkable clinical success. However, the majority of cancer patients fail to respond to immunotherapy or suffer from relapse. Nan ...

EPFL2023